Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tyco downsizing

This article was originally published in The Gray Sheet

Executive Summary

Diversified firm's plan to exit over 50 unidentified business units generating $2.1 bil. in sales - including at least some parts of Tyco Healthcare - will save an estimated $230 mil. by 2005, firm predicts. The restructuring program includes consolidating 219 non-healthcare facilities and cutting 7,200 employees, resulting in fiscal 2004 charges of approximately $400 mil. Fiscal fourth quarter 2003 (ended Sept. 30) results announced Nov. 4 included roughly flat revenues of $9.5 bil. and healthcare sales of $2.2 bil. (up 4.6%). The firm foreshadowed the paring of non-core businesses with the divestiture of its Surgical Dynamics spinal unit in June 2002 (1"The Gray Sheet" June 10, 2002, p. 3)...

You may also be interested in...



Tyco Divestiture Gives Stryker Opportunity To Tie OP-1 With Ray Spinal Cage

Access to Surgical Dynamics' Ray TFC and TFC Unite threaded fusion cages will allow Stryker to compete more effectively with Medtronic in the spinal fusion market, pending FDA approval of bone growth factor products

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel